美国 · SEC FORM 4
Neumora Therapeutics, Inc.
NMRA · Nasdaq · CIK 0001885522 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
27 同一窗口内观察到的 Form 4 交易行
11 sales · 16 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-10-27 · Burow Kristina · $5.0M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Aurora Daljit SinghSee Remarks
○▼○▼○▼○▼○▼
● 买入▼ 卖出○ 其他
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-10-27 · Burow Kristina.
近期 Form 4 活动
3买入
16卖出
16其他 Form 4 交易行
10SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出11 sale line(s) · 仅供背景
其他16 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 6,692,034
- 上期报告
- 6,979,674
- 日均成交量
- 2,491,344
- 回补天数
- 2.7
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-10-27 | Burow Kristina | 买入 (P) | Common Stock | 1,915,700 | USD 2.61 | USD 4,999,977 | SEC 申报 ↗ |
| 2025-10-27 | ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; BYBEE CLINTON; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | 买入 (P) | Common Stock | 1,915,700 | USD 2.61 | USD 4,999,977 | SEC 申报 ↗ |
| 2025-10-27 | ARCH Venture Fund VII, L.P.; ARCH Venture Fund VIII Overage, L.P.; ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners VII, L.P.; ARCH Venture Partners VII, LLC; ARCH Venture Partners VIII, LLC; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC | 买入 (P) | Common Stock | 1,915,700 | USD 2.61 | USD 4,999,977 | SEC 申报 ↗ |
| 2023-11-14 | Burow Kristina | 买入 (P) | Common Stock | 3,357 | USD 11.98 | USD 40,217 | SEC 申报 ↗ |
| 2023-11-14 | ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | 买入 (P) | Common Stock | 3,357 | USD 11.98 | USD 40,217 | SEC 申报 ↗ |
| 2023-11-13 | Burow Kristina | 买入 (P) | Common Stock | 31,653 | USD 11.75 | USD 371,923 | SEC 申报 ↗ |
| 2023-11-13 | ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | 买入 (P) | Common Stock | 31,653 | USD 11.75 | USD 371,923 | SEC 申报 ↗ |
| 2023-11-10 | Burow Kristina | 买入 (P) | Common Stock | 17,275 | USD 11.49 | USD 198,481 | SEC 申报 ↗ |
| 2023-11-10 | ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | 买入 (P) | Common Stock | 17,275 | USD 11.49 | USD 198,481 | SEC 申报 ↗ |
| 2023-11-09 | Burow Kristina | 买入 (P) | Common Stock | 31,079 | USD 10.53 | USD 327,262 | SEC 申报 ↗ |
| 2023-11-09 | ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | 买入 (P) | Common Stock | 31,079 | USD 10.53 | USD 327,262 | SEC 申报 ↗ |
| 2023-11-08 | Burow Kristina | 买入 (P) | Common Stock | 92,251 | USD 11.03 | USD 1,017,821 | SEC 申报 ↗ |
| 2023-11-08 | ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | 买入 (P) | Common Stock | 92,251 | USD 11.03 | USD 1,017,821 | SEC 申报 ↗ |
| 2023-11-07 | Burow Kristina | 买入 (P) | Common Stock | 30,192 | USD 11.50 | USD 347,208 | SEC 申报 ↗ |
| 2023-11-07 | ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | 买入 (P) | Common Stock | 30,192 | USD 11.50 | USD 347,208 | SEC 申报 ↗ |
Form 4 申报证据
35 transaction lines in the latest 365-day window; 142 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-21 | Aurora Daljit Singh | 卖出 (S) | Common Stock | 41,608 | USD 1.60 | USD 66,367 | SEC 申报 ↗ |
| 2026-08-21 | Aurora Daljit Singh | 期权行权／转换 (M) | Common Stock | 41,608 | USD 0.72 | USD 29,958 | SEC 申报 ↗ |
| 2026-08-20 | Aurora Daljit Singh | 卖出 (S) | Common Stock | 134,452 | USD 1.51 | USD 203,023 | SEC 申报 ↗ |
展开近期 Form 4 证据 (18 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-21 | Aurora Daljit Singh | 卖出 (S) | Common Stock | 41,608 | USD 1.60 | USD 66,367 | SEC 申报 ↗ |
| 2026-08-21 | Aurora Daljit Singh | 期权行权／转换 (M) | Common Stock | 41,608 | USD 0.72 | USD 29,958 | SEC 申报 ↗ |
| 2026-08-20 | Aurora Daljit Singh | 卖出 (S) | Common Stock | 134,452 | USD 1.51 | USD 203,023 | SEC 申报 ↗ |
| 2026-08-20 | Aurora Daljit Singh | 期权行权／转换 (M) | Common Stock | 134,452 | USD 0.72 | USD 96,805 | SEC 申报 ↗ |
| 2026-08-19 | Aurora Daljit Singh | 卖出 (S) | Common Stock | 61,918 | USD 1.65 | USD 102,165 | SEC 申报 ↗ |
| 2026-08-19 | Aurora Daljit Singh | 期权行权／转换 (M) | Common Stock | 61,918 | USD 0.72 | USD 44,581 | SEC 申报 ↗ |
| 2026-08-18 | Aurora Daljit Singh | 卖出 (S) | Common Stock | 69,149 | USD 1.59 | USD 109,605 | SEC 申报 ↗ |
| 2026-08-18 | Aurora Daljit Singh | 期权行权／转换 (M) | Common Stock | 69,149 | USD 0.72 | USD 49,787 | SEC 申报 ↗ |
| 2026-08-17 | Aurora Daljit Singh | 卖出 (S) | Common Stock | 146,706 | USD 1.50 | USD 220,296 | SEC 申报 ↗ |
| 2026-08-17 | Aurora Daljit Singh | 期权行权／转换 (M) | Common Stock | 112,686 | USD 0.72 | USD 81,134 | SEC 申报 ↗ |
| 2026-02-17 | Pinto Joshua | 卖出 (S) | Common Stock | 5,967 | USD 3.54 | USD 21,123 | SEC 申报 ↗ |
| 2026-02-17 | Milligan Michael Lee | 卖出 (S) | Common Stock | 1,436 | USD 3.57 | USD 5,127 | SEC 申报 ↗ |
| 2026-02-17 | BERNS PAUL L | 卖出 (S) | Common Stock | 9,819 | USD 3.51 | USD 34,465 | SEC 申报 ↗ |
| 2026-02-17 | Aurora Daljit Singh | 卖出 (S) | Common Stock | 6,165 | USD 3.56 | USD 21,947 | SEC 申报 ↗ |
| 2025-11-11 | Aurora Daljit Singh | 卖出 (S) | Common Stock | 114,703 | USD 2.68 | USD 307,404 | SEC 申报 ↗ |
| 2025-10-27 | Burow Kristina | 买入 (P) | Common Stock | 1,915,700 | USD 2.61 | USD 4,999,977 | SEC 申报 ↗ |
| 2025-10-27 | ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; BYBEE CLINTON; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | 买入 (P) | Common Stock | 1,915,700 | USD 2.61 | USD 4,999,977 | SEC 申报 ↗ |
| 2025-10-27 | ARCH Venture Fund VII, L.P.; ARCH Venture Fund VIII Overage, L.P.; ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners VII, L.P.; ARCH Venture Partners VII, LLC; ARCH Venture Partners VIII, LLC; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC | 买入 (P) | Common Stock | 1,915,700 | USD 2.61 | USD 4,999,977 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | NMRA |
| CIK | 0001885522 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 142 transaction lines from 2023-09-14 to 2026-08-21 44 P purchase lines · 32 S sale lines · 66 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.